Background: Janus kinase (JAK)-mediated cytokine signalling contributes to local and systemic inflammation in hidradenitis suppurativa (HS).
Objectives: To describe the safety and efficacy results from two multicentre phase II trials of the JAK1 inhibitor INCB054707 in patients with moderate-to-severe HS.
Methods: Patients received open-label INCB054707 15 mg once daily (QD; Study 1) or were randomized to INCB054707 30, 60 or 90 mg QD or placebo (3 : 1 within each cohort; Study 2) for 8 weeks. Eligible patients were aged 18-75 years and had moderate-to-severe HS (Hurley stage II/III disease), lesions present in at least two anatomical locations, and a total abscess and inflammatory nodule count ≥ 3. The primary endpoint for both studies was safety and tolerability. Secondary endpoints included HS Clinical Response (HiSCR) and other efficacy measures.
Results: Ten patients were enrolled in Study 1 (15 mg INCB054707) and 35 in Study 2 (INCB054707: 30 mg, n = 9; 60 mg, n = 9; 90 mg, n = 8; placebo, n = 9). Overall, 70% of patients in Study 1 and 81% of patients receiving INCB054707 in Study 2 experienced at least one treatment-emergent adverse event; 30% and 42% of patients, respectively, had at least one treatment-related adverse event. Among the evaluable patients, three (43%) in Study 1 and 17 (65% overall: 30 mg, 56%; 60 mg, 56%; 90 mg, 88%) receiving INCB054707 vs. 4 patients (57%) receiving placebo in Study 2 achieved HiSCR at week 8.
Conclusions: INCB054707 was well tolerated, with responses observed in patients with moderate-to-severe HS. The safety and efficacy findings from these studies demonstrate proof of concept for JAK1 inhibition in HS. The studies are registered on ClinicalTrials.gov (NCT03569371 and NCT03607487).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314604 | PMC |
| http://dx.doi.org/10.1111/bjd.20969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chronic Prurigo.
J Dtsch Dermatol Ges
June 2024
Department of Dermatology and Competence Center for Chronic Pruritus (KCP), University Hospital Münster, Münster, Germany.
Article Synopsis
- * The main type of CPG is chronic nodular prurigo (CNPG), and recent advances in understanding its causes have led to new treatment options.
- * Dupilumab is the first treatment approved for moderate to severe CNPG, while several other promising therapies, including biologics and Janus kinase inhibitors, are currently undergoing clinical trials.
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
J Am Acad Dermatol
March 2024
Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Background: Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.
Objective: To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS.
Methods: This placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive povorcitinib 15, 45, or 75 mg or placebo for 16 weeks.
Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments.
Am J Clin Dermatol
January 2024
Department of Dermatology, Center for Chronic Pruritus, University Hospital Münster, Von-Esmarch-Str. 58, 48149, Münster, Germany.
Article Synopsis
- Chronic prurigo (CPG) is a painful skin condition characterized by intense itch lasting over six weeks, which leads to skin lesions and frequent scratching, significantly impacting patients' mental health and quality of life.
- Chronic prurigo of nodular type (CNPG) is the most common form of CPG and this review explores its clinical features, disease burden, and underlying mechanisms while highlighting current and emerging therapies.
- Dupilumab is the first approved systemic treatment for CNPG, with ongoing clinical trials investigating other promising therapies, including biologics and small molecules, aimed at improving patient care and understanding of the disease.
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature.
Medicina (Kaunas)
April 2023
Section of Dermatology-Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
Article Synopsis
- - Hidradenitis suppurativa (HS) is a painful and chronic skin condition affecting areas with apocrine glands, and there’s a significant need for better treatment options.
- - The review analyzed 56 manuscripts about the use of JAK inhibitors for HS, ultimately selecting 25 relevant articles, including one clinical trial and various case studies showing some promising results.
- - Current studies indicate that JAK inhibitors like INCB054707, upadacitinib, and tofacitinib may be effective and safe for treating HS, but more large-scale research is needed to confirm these findings and improve treatment options.
Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 Studies.
Int J Mol Sci
April 2023
Incyte Corporation, Wilmington, DE 19803, USA.
Article Synopsis
- The study investigates the effects of the JAK1-selective inhibitor povorcitinib on patients with moderate-to-severe hidradenitis suppurativa (HS) through transcriptomic and proteomic analyses.
- Skin biopsies and blood samples from participants revealed significant changes in gene expression and protein levels, particularly with the 30 mg dosage of povorcitinib.
- Results indicate that povorcitinib effectively downregulates HS-related inflammatory markers and suggests that JAK1 inhibition may offer a new therapeutic approach to treating HS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!